000126920 001__ 126920
000126920 005__ 20240228140854.0
000126920 0247_ $$2doi$$a10.1007/s11307-014-0795-3
000126920 0247_ $$2pmid$$apmid:25319765
000126920 0247_ $$2ISSN$$a1536-1632
000126920 0247_ $$2ISSN$$a1860-2002
000126920 0247_ $$2altmetric$$aaltmetric:2787852
000126920 037__ $$aDKFZ-2017-02948
000126920 041__ $$aeng
000126920 082__ $$a610
000126920 1001_ $$0P:(DE-HGF)0$$aKratochwil, C.$$b0$$eFirst author
000126920 245__ $$aSUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.
000126920 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2015
000126920 3367_ $$2DRIVER$$aarticle
000126920 3367_ $$2DataCite$$aOutput Types/Journal article
000126920 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522312396_19475
000126920 3367_ $$2BibTeX$$aARTICLE
000126920 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126920 3367_ $$00$$2EndNote$$aJournal Article
000126920 520__ $$aThe goal of our study was to quantify the expression of the somatostatin receptors (SSTR2) using the maximum standardized uptake value (SUVmax) of [(68)Ga]DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) positron emission tomography (PET)-computed tomography (CT) in liver metastases of patients with neuroendocrine tumors (NETs) prior to peptide receptor radiation therapy (PRRT) and compare the initial tumor uptake with the final treatment outcome.SSTR2 expression of the 60 liver metastases in 30 NET patients was assessed at baseline and after PRRT by measuring SUVmax, tumor to spleen ratio (T/S ratio), and tumor to liver ratio (T/L ratio). Based on morphological changes and tumor size measured at baseline and follow-up contrast-enhanced CT (after three cycles of PRRT), lesions were divided into two groups by the following: (i) responding (n = 40) and (ii) non-responding (n = 20).Statistically significant differences were observed in the mean SUVmax for non-responding vs. responding lesions at baseline (18.00 ± 3.59 vs. 33.55 ± 4.62, p < 0.05) and for the mean T/S ratio (1.20 ± 0.37 vs. 1.90 ± 0.45, p < 0.05) and the mean T/L ratio (3.15 ± 0.53 vs. 4.97 ± 0.62, p < 0.05). Using the receiver operating characteristic curves, SUVmax was found a better metric than both T/L ratio and T/S ratio (area under the curve (AUC) of SUVmax 0.87; T/L ratio 0.78; T/S ratio 0.73) as a stratification criterion. Using a threshold value of >16.4 for SUVmax, the sensitivity and specificity in predicting responding lesions were 95 and 60 %, respectively.We propose a SUVmax cutoff of >16.4 from [(68)Ga]DOTATOC-PET-CT to select patients for PRRT. A T/L ratio >2.2 might present a scanner-independent criterion that enables the translation of our results to other institutions. However, the robustness of this arbitrary unit still needs to be evaluated with different PET scanners.
000126920 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000126920 588__ $$aDataset connected to CrossRef, PubMed,
000126920 650_7 $$2NLM Chemicals$$aContrast Media
000126920 650_7 $$2NLM Chemicals$$aGa(III)-DOTATOC
000126920 650_7 $$2NLM Chemicals$$aOrganometallic Compounds
000126920 650_7 $$2NLM Chemicals$$aPeptides
000126920 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000126920 650_7 $$2NLM Chemicals$$aReceptors, Somatostatin
000126920 650_7 $$2NLM Chemicals$$asomatostatin receptor subtype 2, human
000126920 650_7 $$0RWM8CCW8GP$$2NLM Chemicals$$aOctreotide
000126920 7001_ $$0P:(DE-HGF)0$$aStefanova, M.$$b1
000126920 7001_ $$0P:(DE-HGF)0$$aMavriopoulou, E.$$b2
000126920 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, T.$$b3$$udkfz
000126920 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, A.$$b4$$udkfz
000126920 7001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, A.$$b5$$udkfz
000126920 7001_ $$0P:(DE-HGF)0$$aMier, W.$$b6
000126920 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, U.$$b7$$udkfz
000126920 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b8$$eLast author$$udkfz
000126920 773__ $$0PERI:(DE-600)2079211-6$$a10.1007/s11307-014-0795-3$$gVol. 17, no. 3, p. 313 - 318$$n3$$p313 - 318$$tMolecular imaging & biology$$v17$$x1860-2002$$y2015
000126920 909CO $$ooai:inrepo02.dkfz.de:126920$$pVDB
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126920 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000126920 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000126920 9141_ $$y2015
000126920 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126920 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126920 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL IMAGING BIOL : 2015
000126920 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126920 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126920 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126920 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126920 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126920 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126920 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126920 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126920 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000126920 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000126920 980__ $$ajournal
000126920 980__ $$aVDB
000126920 980__ $$aI:(DE-He78)E060-20160331
000126920 980__ $$aI:(DE-He78)C060-20160331
000126920 980__ $$aUNRESTRICTED